Navigation Links
Tris Pharma Announces Acceptance of Its First Two NDAs
Date:5/13/2009

pill."

"FDA's acceptance of our two NDAs validates Tris' OralXR platform, and is an important milestone for the company," says Tris Pharma CEO and Founder Ketan Mehta. "We have an exciting future, with a robust pipeline of more than 20 extended release products in different therapeutic categories currently in development."

Tris' drug delivery technology also offers other improvements over those used for the older products. To manufacture the cardiovascular drug, the company uses a safe water-based process, replacing the need for the toxic organic solvents used in the older products. This new aqueous solvent, coupled with Tris' patent-pending manufacturing process, also improves product stability and batch-to-batch uniformity.

About Tris Pharma:

Tris Pharma is a privately owned, product-focused, specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. Through its OralXR platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms where by patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. The company has more than 30 Rx and OTC products in development with pharmaceutical partners. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey. For more information visit http://www.trispharma.com


'/>"/>
SOURCE Tris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
2. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
3. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
6. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
7. Transcept Pharmaceuticals to Report First Quarter 2009 Results
8. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
9. Pharmateks Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
10. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
11. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ViewRay™, a privately held medical device ... exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange ... for the treatment of cancer in Japan ... the world,s first and only MRI-guided radiation therapy system ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... Increasing sophistication among enterprise buyers of language services ... 2015, says Moravia CMO, Renato Beninatto ... market research firm Common Sense Advisory, 15 percent of ... and localization needs. "From a language industry perspective, this ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Dr. Michael Klein , director of the Food and Drug Administration (FDA) Controlled Substance ... abuse of prescription drugs.   , , , ... , , ... , , Learn more ...
... , July 28, 2010 , ... - Company Expands Market-leading Family of Neurovascular Stents , ... Boston Scientific Corporation (NYSE: BSX ... fourth-generation,intracranial aneurysm stent system designed for use in conjunction with,endovascular coiling to treat wide-necked ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D. 2Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 2Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 3Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 4
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... has enough capacity for typical season; experts less sure about ... current swine flu outbreak is raising critical questions about the ... logistics of getting it to the people who need it. ... into this fall,s production of seasonal influenza vaccine, experts say. ...
... war, blast injuries have become the signature injuries. These ... cause damage to the visual system and the visual processing ... wrong with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, ... LAKE, N.Y., May 18 The journey home is a ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... Preliminary results from the first-of-its-kind Clinical Evaluation and ... at the Society of Gastroenterology Nurses and Associates, Inc. ... The study indicated that while there are written endoscope ... in the study, significant variation in manual reprocessing takes ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... from Alcon and Initial Payments from New Galderma ... Calif., May 18 NovaBay Pharmaceuticals, Inc. (NYSE ... company developing first-in-class anti-infective products for the treatment ... without causing resistance, reported today its financial results ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: